A non-interventional study of biosimilar granulocyte colony-stimulating factor as prophylaxis for chemotherapy-induced neutropenia in a community oncology centre
Objectives: Prophylaxis with granulocyte colony-stimulating factor (G-CSF) reduces the severity of chemotherapy-induced neutropenia. Biosimilar G-CSF is now approved for use, based on comparable efficacy, safety and quality with the originator product. Methods: We conducted a retrospective review of...
Main Authors: | Karl Verpoort MD, Thomas M. Möhler MD, PhD |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2012-11-01
|
Series: | Therapeutic Advances in Medical Oncology |
Online Access: | https://doi.org/10.1177/1758834012461330 |
Similar Items
-
Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: systematic review and meta-analysis
by: Stevenson Matt D, et al.
Published: (2011-09-01) -
Routine Primary Prophylaxis for Febrile Neutropenia with Biosimilar Granulocyte Colony-Stimulating Factor (Nivestim) or Pegfilgrastim Is Cost Effective in Non-Hodgkin Lymphoma Patients undergoing Curative-Intent R-CHOP Chemotherapy.
by: Xiao Jun Wang, et al.
Published: (2016-01-01) -
A multi-centre study comparing granulocyte-colony stimulating factors to antibiotics for primary prophylaxis of docetaxel-cyclophosphamide induced febrile neutropenia
by: Mark Clemons, et al.
Published: (2021-08-01) -
Recombinant granulocyte colony stimulating factor biosimilars. Quality assessment
by: Zh. I. Avdeeva, et al.
Published: (2018-02-01) -
Evaluating the Prognostic Role of Monocytopenia in Chemotherapy-Induced Febrile Neutropenia Patients Treated with Granulocyte Colony-Stimulating Factor
by: Alshari O, et al.
Published: (2021-09-01)